Robert J. Gould, President & CEO at Epizyme, Inc. (EPZM), sold 60,000 shares at $22.40 ($1.3M) on 2015-08-03, disclosed to the SEC on 2015-08-05.
Scheduled sale ($1.3M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.94 | 55,800 | $1.2M | 92.9% |
| 2 | $22.40 | 4,200 | $94K | 7.1% |
| Total | $21.97 avg | 60,000 | $1.3M | 100% |
| Filing → |
| FULC | SELL | 2026-01-06 | $356K | — | Filing → |
| FULC | SELL | 2025-11-21 | $165K | — | Filing → |
| FULC | SELL | 2023-01-13 | $101K | — | Filing → |